Table 2.

Patient and tumor characteristics of esophageal adenocarcinomas

	Overall collective (n = 429)		Non-amplified (n = 408)		Amplified (n = 21)
Sex
Male	385	90.1%	365	89.5%	20	97.3%
Female	44	10.3%	43	10.5%	1	4.9%
Preoperative treatment
None	177	41.4%	164	40.2%	13	61.9%
Neoadjuvant	252	58.6%	244	59.8%	8	38.1%
Age
< 65	220	51.4%	212	51.9%	8	38.1%
> 65	208	48.5%	196	48.0%	13	61.9%
Tumor Stage
(y)pT1	92	21.5%	90	22.1%	2	9.5%
(y)pT2	82	19.2%	77	18.9%	5	23.8%
(y)pT3	245	57.0%	231	56.6%	13	61.9%
(y)pT4	11	2.6%	10	2.5%	1	4.8%
Lymph node metastasis
(y)pN0	170	39.6%	164	40.2%	6	28.6%
(y)pN1	159	37.1%	151	37.0%	8	38.1%
(y)pN2	53	12.4%	53	13.0%	0	0.0%
(y)pN3	47	11.0%	40	9.8%	7	33.3%

429 patients were analyzed